ROS1+ NSCLC tumors made up of 78.8% of the ROS1+ solid tumors, followed by ROS1+ GBM (6.9%), and ROS1+ breast cancer (2.7%) followed by 1–3 cases of ROS1 fusions among the the rest of the 13 tumor types (Fig. 1A body figure, Fig. 1B pie chart). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.